Aldeyra Therapeutics (ALDX) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Aldeyra Therapeutics ALDX is currently developing the following drugs: Adx-629, Vehicle Ophthalmic Solution, Reproxalap Ophthalmic Solution (0.25%), Adx-629 (Open-Label), Reproxalap Ophthalmic Solution (0.25%), Xiidra (5% Lifitegrast Ophthalmic Solution), Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.25%), Vehicle Opthalmic Solution, Adx-2191 (Intravitreal Methotrexate 0.8%), Standard Surgical Care Procedure, Reproxalap Ophthalmic Solution (0.25% Novel Formulation) Qid To Bid, Vehicle Ophthalmic Solution (0.25% Novel Formulation) Qid To Bid, Reproxalap Ophthalmic Solution (0.25%) Qid, Vehicle Ophthalmic Solution Qid, Reproxalap Ophthalmic Solution (0.25%) Qid To Bid, Vehicle Ophthalmic Solution Qid To Bid, Vehicle Ophthalmic Solution, Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Adx-102 1% Topical Dermal Cream (Reproxalap), Vehicle Of Adx-102 Topical Dermal Cream, Vehicle Ophthalmic Solution, Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.1%), Adx-102 Ophthalmic Solution (0.5%), Adx-102 Ophthalmic Solution (0.1%), Adx-102 Ophthalmic Lipid Solution (0.5%), Adx-102 Ophthalmic Solution (0.5%), Vehicle Of Adx-102 Ophthalmic Solution. These drug candidates are in various stages of clinical development as the company works toward FDA approval.